Terence W. Friedlander


Genitourinary oncologist
Medical oncologist who loves to travel and play tennis

Dr. Terence Friedlander specializes in cancers of the genital and urinary organs, in particular bladder and prostate cancers. His research focuses on understanding the basic biology of these diseases and developing new ways to overcome resistance to treatments.

Friedlander earned his medical degree at New York University School of Medicine and completed a residency in internal medicine at UCSF. He received a Fulbright scholarship in 2006 to study medical ethics, and he completed a fellowship in hematology and oncology at UCSF, when he served as chief fellow. He has also received an American Society of Clinical Oncology Young Investigator Award.

Friedlander is a member of the American Society of Clinical Oncology and American Association for Cancer Research.

  • Education

    New York University School of Medicine, 2003

  • Residencies

    UCSF Medical Center, Internal Medicine, 2006

  • Fellowships

    UCSF Medical Center, Hematology-Oncology, 2010

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages


With so many new options available for urologic cancers, my hope is that we can harness these treatments to help all our patients.

Where I see patients (2)

    My reviews


    Overall Experience
    123 Ratings
    Explained things in a way that was easy to understand
    121 Ratings
    Did the doctor pay attention to your concerns
    123 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    121 Ratings
    Knew the important information about your medical history
    121 Ratings
    The provider showed respect for what you had to say
    123 Ratings
    The provider spent enough time with me
    122 Ratings
    Decorative Caduceus

    A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

    Descriptive statistics will be used to summarize results.


    Decorative Caduceus

    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combina...

    Objective response rate, defined as the proportion of participants with a CR or PR on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.


    Decorative Caduceus

    TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Ad...

    Assess the safety profile, dose limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TTX-030 when administered intravenously (IV) as a single agent and in combination with agents in speci...